Related Experiment Video
Updated: Apr 27, 2026

Site Specific Lysine Acetylation of Histones for Nucleosome Reconstitution using Genetic Code Expansion in Escherichia coli
Published on: December 26, 2020
Identification of novel covalent ligands that disrupt Acetyl-Lysine binding to the SETDB1 tudor domain
Jun Ma1, Yunyuan Huang1, Tao Zheng2
1Key Laboratory of Pesticide and Chemical Biology of Ministry of Education, Hubei Key Laboratory of Genetic Regulation and Integrative Biology, School of Life Sciences, Central China Normal University, Wuhan, 430079, China.
Abstract:
SETDB1 is a histone methylation reader that recognizes the H3K9me2/K14ac marks via two pockets (Kme and Kac) within its triple Tudor domain. Overexpression of SETDB1 is frequently associated with cancer and neurodegenerative diseases, highlighting its potential as a therapeutic target. However, ligands targeting the Kac pocket of the triple Tudor domain remain poorly explored. In this study, differential scanning fluorimetry (DSF) coupled with iodoacetamide-rhodamine (IA-rhodamine, IAR) screening was used to identify two covalent ligands, XY047 and XY087, which primarily target Cys329 and occupy the Kac pocket of the SETDB1 Tudor domain. Cell lysate-based assay further confirmed their binding activity. These findings provide valuable tools for investigating the biological functions of SETDB1 in disease and advancing the development of targeted therapeutics.
Insights
Researchers identified new covalent ligands, XY047 and XY087, targeting the SETDB1 Tudor domain's Kac pocket. These compounds are valuable tools for studying SETDB1's role in diseases like cancer and neurodegeneration.
Area of Science:
- Biochemistry
- Epigenetics
- Chemical Biology
Background:
- SETDB1 is a histone methylation reader implicated in cancer and neurodegenerative diseases.
- Its Tudor domain recognizes H3K9me2/K14ac marks through Kme and Kac pockets.
- Targeting the SETDB1 Kac pocket presents a therapeutic opportunity, but ligands are underexplored.
Purpose of the Study:
- To identify novel covalent ligands targeting the SETDB1 Tudor domain's Kac pocket.
- To develop chemical tools for investigating SETDB1's biological functions in disease.
Main Methods:
- Differential scanning fluorimetry (DSF) screening.
- Iodoacetamide-rhodamine (IA-rhodamine, IAR) assay.
- Cell lysate-based binding assays.
Main Results:
- Two covalent ligands, XY047 and XY087, were identified.
- These ligands primarily target Cys329 and bind to the SETDB1 Tudor domain's Kac pocket.
- Binding activity was confirmed in cell lysates.
Conclusions:
- XY047 and XY087 are effective covalent inhibitors of the SETDB1 Tudor domain.
- These ligands serve as valuable chemical probes for SETDB1 research.
- The findings advance the development of SETDB1-targeted therapeutics for cancer and neurodegeneration.
Related Concept Videos
Ligand Binding and Linkage
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...

